Leishmaniasis, a parasitic disease caused by different members of the genus *Leishmania*, is a vector-borne disease transmitted by *Phlebotomous* spp (sandflies). The disease has three different forms of clinical presentation, including visceral leishmaniasis (VL) (the most fatal), mucocutaneous leishmaniasis and the cutaneous form (CL), which is self healing in most cases. According to the WHO,[@b1-asm-1-73] leishmaniasis is endemic in more than eighty countries of the tropical and subtropical zones.

Disease severity is largely affected by the host immune response regardless of the species or strain responsible for causing the disease. Gamma-interferon and nitric oxide production by T helper-1 cells, which dominate cell-mediated immunity, usually increases the host ability to resist disease while susceptibility and disease progression are mostly associated by the T helper-2 type of immune response, which is the dominant type in humoral immunity.[@b2-asm-1-73]--[@b4-asm-1-73] Thus, in both visceral and cutaneous forms of the disease, and regardless of the different clinical presentations in each, resistance as well as recovery are linked to Th1 type of response dominancy while case deterioration is linked to Th2 type of response dominancy.[@b5-asm-1-73] In addition, suppression of cellular immunity (Th1 response) that results in a negative leishmanin skin test (delayed type hypersensitivity reaction to leishmania antigen) is a major characteristic of visceral leishmaniasis.[@b6-asm-1-73]

As delayed type hypersensitivity was found to be restored upon effective treatment,[@b7-asm-1-73] immunosuppression was also shown to be quickly reversible following successful chemotherapy.[@b8-asm-1-73] Moreover, intracellular killing of *leishmania* parasites by interferon gamma-activated macrophages is the main mechanism for control of visceral leishmaniasis by both adaptive and innate immune responses.[@b9-asm-1-73] On the other hand, an early humoral response preceding the abnormalities of the cellular response has been detected through the elevation of antileishmanial specific antibodies of almost all antibody classes.[@b10-asm-1-73],[@b11-asm-1-73] These antibodies may result in the acquisition of naturally protective immunity in endemic areas as large populations with asymptomatic or subclinical infections were found to have high levels of specific antileishmanial antibodies.[@b12-asm-1-73]

PATIENTS AND METHODS
====================

We conducted a cross-sectional laboratory-based study in visceral leishmaniasis patients referred for diagnosis to the laboratory of the Institute of Endemic Diseases from the Tropical Medicine Hospital, Suba University Hospital, Omdurman and Khartoum Teaching Hospitals.

Patients with a positive direct agglutination test (DAT) gave informed consent and were enrolled after confirmation of infection by parasitological methods. Smears from lymph node aspiration were prepared and stained with Gimsa and all the study subjects had positive results (presence of Leishman-Donovan (LD) bodies). Five of the 25 VL patients enrolled in this study were resistant to pentostam (sodium stibogluconate) according to follow-up records.

In smear-positive patients, 10 mL of blood were drawn into heparinized vacutainer tubes. The tubes were centrifuged at 2000 rpm for separation of plasma, which was removed to a new tube. The rest of the blood was diluted with an equal volume of complete media (RPMI 1640). In a 15-mL tube, 3 mL of Ficoll-Hypaque (Histopaque-1077, Sigma Aldrich) was added and the diluted blood was carefully layered on the Ficoll-Hypaque. The tubes were then centrifuged at 2000 rpm for 15 minutes. The lymphocytes layer in the interphase was collected and transferred to a new tube. Cells were washed twice with 10 mL of complete media. Cells were then pelleted and the pellets were resuspended in 2 mL of complete media to concentrate the cells.

Autochthonous isolates MHOM/SD/00/MW1 (zymodeme MON-74) of *L major*, were isolated from a Sudanese CL patient and MHOM/SD/00/MW81 (zymodeme MON-82) of *L donovani* isolated from a Sudanese VL patient and grown in the lab in stationary phase were used for protein preparation. Cultures were centrifuged, the pellets washed three times using sterile phosphate buffered saline (PBS), then freezed and thawed six times in liquid nitrogen and a water bath at 55°C. The protein concentration was then measured and adjusted to the desired concentration and stored frozen.

Into a sterile 24-well flat-bottomed plate, aliquots of cells (10^6^ cells per mL of complete media) were placed together with one of the leishmania antigens (MW1 and MW81 lysates) each in a separate well in a final concentration of 100 μg/mL. For each sample, a well with cultured unstimulated cells was kept as a negative control and a well stimulated with phytohaemagglutinin mitogen (PHA) was kept as a positive control. Lymphocytes were cultured at 37°C in a humidified, 5% CO~2~ incubator. After 72 hours, the wells were harvested by centrifugation at 6000 rpm for 3 minute to remove the cells. The supernatant was separated and stored at -20°C in small aliquots for later cytokine analysis.

Cytokines were determined by sandwich ELISA using a BD OptEIA ELISA Set for the human cytokines interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), tumor necrosis factor beta (TGFβ) and interleukin 10 (IL-10). ELISA was performed according to manufacturer instructions.

Data was analyzed by statistical software package, Version 16 (SPSS Inc., Chicago, IL, USA). Descriptive data analysis was used to visualize differences within the data. Independent sample t-tests and one-way ANOVA were used for comparison of means.

RESULTS
=======

In both groups of patients there was a significant increase in interferon gamma (IFNγ) levels in response to the homologous visceral antigen compared with heterologous cutaneous antigen (*P*\<.001) ([Figure 1](#f1-asm-1-73){ref-type="fig"}). However, there was no significant difference between the drug-susceptible and drug-resistant patients peripheral mononuclear cells (PMNC) in production of this cytokine. Interleukin-10 (IL-10) increased slightly when the lymphocytes were stimulated by PHA and *L major* lysate compared to non-stimulated cells and cells stimulated with *L donovani* antigen ([Figure 2](#f2-asm-1-73){ref-type="fig"}). Neither group of patients had a significant difference in IL-10 production.

Significant high levels of tumor necrosis factor alpha (TNFα) were detected in culture supernatants, with special reference to the cellular response to *L major* antigen compared to L donovani antigen (*P*\<.001) ([Figure 3](#f3-asm-1-73){ref-type="fig"}). No significant difference was observed between the two groups of patients. Transforming growth factor beta (TGFβ) from stimulated patients lymphocytes was secreted in statistically significant amounts in patients reported as drug resistant. (*P*\<.001) ([Figure 4](#f4-asm-1-73){ref-type="fig"}). This was true for both *L major* and *L donovani* antigens.

DISCUSSION
==========

The high levels of IFNγ detected in response to leishmania antigens, with more specific stronger response to *L donovani* antigen, are consistent with a previous study, which reported that high levels of IFNγ are secreted at the initial stages of exposure to the parasites as observed in seroconverted or sub-clinically infected individuals in an endemic area.[@b13-asm-1-73] Another study that examined the cells of cutaneous leishmaniasis patients recorded that both CD8+ cells and CD4+ cells are sources of biologically active IFNγ when the cells of patients are stimulated in vitro with *L major* antigen compared with control cells.[@b14-asm-1-73]

Similarly, considerable amounts of TNFα were detected in the cells of patients included in this study, which is consistent with a previous finding by Pirmez, et al.[@b15-asm-1-73] Another study found high TNFα levels in the serum of active VL patients compared to patients with cryptic leishmanial infection (asymptomatic, self-healing subclinical infection, and posttreatment VL cases) and normal volunteers.[@b16-asm-1-73] Moreover, VL is an extremely rare example of opportunistic infection in patients treated with TNFα antagonists. A few cases have been described for patients developing VL under biological therapy.[@b17-asm-1-73] Another study found that levels of circulating TNFα, assessed by ELISA, were higher in patients than in healthy controls, and declined significantly with improvement in clinical and laboratory parameters after successful treatment, but these plasma levels when evaluated by cytotoxicity assay were not well defined, a fact that could be linked to the presence of factor(s) that can affect both the release and activity of TNFα.[@b18-asm-1-73]

We detected low and insignificant levels of IL-10. The production of IL-10 during *L donovani* infection, and the role of IL-10 in the regulation of immune responsiveness during visceral leishmaniasis is well documented.[@b19-asm-1-73] The results of our study are not consistent with previous investigations on Brazilian patients, which showed that IL-10 production from *L chagasi* antigen-stimulated PBMC cultures of acute VL patients was significantly higher than in cured individuals, whereas asymptomatic leishmanin skin test (LST)-positive individuals did not produce IL-10.[@b20-asm-1-73] A previous study proved that the high parasite load in VL is strongly correlated with a high level of IL-10, implicating IL-10 as a marker of disease severity that can be assayed for diagnosis as well as prognosis of both VL and post-kala-azar dermal leishmaniasis (PKDL),[@b21-asm-1-73] Investigators in 2011 nominated IL-10 as an approach to therapy in human VL following the fact that IL-10 neutralization promoted parasite killing in and complete clearance in the majority of VL patients.[@b22-asm-1-73] Moreover, the splenic cells secreted increased levels of both TNFα and IFNγ under IL-10-neutralizing conditions.[@b22-asm-1-73] Lymphocytes are the known source of IL-10 and previous data implicated CD25-Foxp3 T cells as the source of IL-10 in the pathogenesis of human VL.[@b23-asm-1-73]

In the present study, significantly high levels of TGFβ were detected, especially in patients with treatment failure. These results were consistent with previous reports that showed TGFβ production in visceral leishmaniasis.[@b24-asm-1-73],[@b25-asm-1-73] A previous study from India was consistent with out results in that they found that the retention and maintenance of residual IL-10 and TGF-beta in some sodium antimony gluconate-treated individuals and the elevation of IL-10 and TGF-beta in PKDL, a sequel to kala-azar, probably reflects the role of these cytokines in reactivation of the disease in the form of PKDL. Contrastingly, ambisome treatment of VL resulted in negligible TGF-beta levels and absolute elimination of IL-10, reflecting the better therapeutic activity of ambisome and its probable role in the recent decline in PKDL occurrences.[@b26-asm-1-73] Moreover, elucidation of immune responses in Indian PKDL patients revealed a spectral pattern of disease progression where disease severity could be correlated inversely with lymphoproliferation and directly with TGF-beta, IL-10, and antibody production.[@b26-asm-1-73]

In conclusion, in VL patients, IFNγ and TNFα are produced in high levels in response to in vitro restimulation, which means that the parasitic infection, although virulent and chronic, does not render patients as immunocompromised. Insignificant production of IL-10 was reported. TGFβ is mostly associated with the pathology of the disease since significant increases are associated with treatment failure.
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